The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000477325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/03/2026
Date registered
Help: Date registered
17/04/2026
Date last updated
Help: Date last updated
17/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Population pharmacokinetics of isradipine in children with acute hypertension
Scientific title
Population pharmacokinetics of isradipine in children with acute hypertension
Additional trial identifiers [1] 316898 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
acute hypertension 341312 0
Condition category
Condition code
Cardiovascular 337386 337386 0 0
Hypertension

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
Participant will be receiving isradipine AS PART OF standard care (i.e. regardless of their involvement in this study). participant will be observed until post 8 hours of subsequent isradipine dose (can be either 2nd or 3rd dose).

dosage and duration given as per current hospital guideline.
Starting dose 0.05-0.1 mg/kg (max 5 mg); dose may be repeated after one hour if required (usually dosing is 2-4 times per day) Titrate to effect, maximum daily dose 0.8 mg/kg/day (maximum 20 mg/day)
adherence not applicable as isradipine dosing regimen is when required basis (i.e prn)
Intervention code [1] 333629 0
Not applicable
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344925 0
this will be assessed as a composite outcome Population estimates of conventional pharmacokinetic parameters including ka (absorption rate constant), VC/F (central volumes of distribution; F relative to bioavailability CL/F (clearance) VP/F and Q/F (peripheral volumes of distribution and respective inter-compartmental clearance(s)), area under the concentration-time curve (AUC), and elimination half-live(s) will then be calculated
Timepoint [1] 344925 0
A single sample collected 1-3h, 3-4h, 4-6h, 6-8h post 1st dose and 4-6h after a subsequent dose, for up to two doses.
Secondary outcome [1] 459787 0
blood pressure
Timepoint [1] 459787 0
at 30min, 1 hour, 2hour, 4 hours, 6 hour, 8 hours of isradipine dose

Eligibility
Key inclusion criteria
1) Children, aged 1 month to 17 years of age prescribed isradipine to manage acute hypertension; 2) Written informed consent
Minimum age
1 Months
Maximum age
17 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Hypersensitivity to isradipine or any component of the formulation; 2) previous dihydropyridine hypersensitivity

Study design
Purpose
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 321494 0
Charities/Societies/Foundations
Name [1] 321494 0
Perth Children's Hospital Foundation
Country [1] 321494 0
Australia
Primary sponsor type
Government body
Name
Child and Adolescent Health Service
Address
Country
Australia
Secondary sponsor category [1] 324274 0
None
Name [1] 324274 0
Address [1] 324274 0
Country [1] 324274 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320028 0
Child and Adolescent Health Service Human Research Ethics Committee
Ethics committee address [1] 320028 0
Ethics committee country [1] 320028 0
Australia
Date submitted for ethics approval [1] 320028 0
01/08/2024
Approval date [1] 320028 0
14/08/2024
Ethics approval number [1] 320028 0
RGS0000007049

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149190 0
Dr Kwi Moon
Address 149190 0
Perth Children's Hospital 15 Hospital Avenue, Nedlands WA 6009
Country 149190 0
Australia
Phone 149190 0
+618 62562222
Fax 149190 0
Email 149190 0
Contact person for public queries
Name 149191 0
Kwi Moon
Address 149191 0
Perth Children's Hospital 15 Hospital Avenue, Nedlands WA 6009
Country 149191 0
Australia
Phone 149191 0
+618 62562222
Fax 149191 0
Email 149191 0
Contact person for scientific queries
Name 149192 0
Kwi Moon
Address 149192 0
Perth Children's Hospital 15 Hospital Avenue, Nedlands WA 6009
Country 149192 0
Australia
Phone 149192 0
+618 62562222
Fax 149192 0
Email 149192 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.